The FDA has expanded approval for Pfizer’s respiratory syncytial virus (RSV) vaccine, Abrysvo, to include adults aged 18–59 years who are at higher risk of lower respiratory tract disease from the virus due to chronic conditions.
BirchBioMed announced the authorisation from Health Canada to conduct its Phase II/III randomised clinical trial of a naturally based compound, FS2, at multiple centres of expertise throughout Canada.
Avantor and NIBRT have formed a new partnership to supply advanced Masterflex equipment, essential products and expert training to foster innovations in biopharma manufacturing.
Bioptimus announced that its H-optimus-0 foundation model is now integrated into Proscia’s Concentriq Embeddings, enabling data scientists and researchers in pathology and life sciences to achieve breakthroughs in AI development.
Ten entrepreneurial life science and technology businesses have begun the immersive Discovery Spark programme, with a prize package worth over £50,000 up for grabs.
These will be used to package a medication indicated for the prophylaxis and treatment of seasonal and perennial allergic rhinitis, as well as vasomotor rhinitis.
University of Birmingham Enterprise announces the launch of Biocell Energetics, to provide profiling and testing services that assess, in real-time, how living cells produce energy.
